Inhibitors of articular calcium crystal formation

John D. Sallis, Herman S Cheung

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The coexistence of calcium phosphate and calcium pyrophosphate crystals in osteoarthritis is a well-described phenomenon. In addition to deposition in articular cartilage, the crystals induce numerous changes to biochemical parameters in the surrounding fluid. This survey discusses crystal-inhibitor interactions whereby defining the molecular structure of crystals assists in an optimal inhibitor design. Crystal growth studies in the presence and absence of a test compound can generate data on crystal face changes. Together with knowledge of the inhibitors' molecular structure, computer modeling can portray crystal-inhibitor interactions. Few inhibitors have been tested in both in vitro and in vivo phases. One exception is phosphocitrate. This compound inhibits both the development of specific calcium crystals and crystal-induced intracellular changes. Animal studies confirm a strong action on pathologic calcification. The recently described phosphocitrate in a mixed calcium and sodium salt, yet to be tested in a guinea pig osteoarthritis model, appears to be an even more powerful inhibitor.

Original languageEnglish
Pages (from-to)321-325
Number of pages5
JournalCurrent Opinion in Rheumatology
Volume15
Issue number3
DOIs
StatePublished - May 1 2003

Fingerprint

Molecular Structure
Osteoarthritis
Joints
Molecular Computers
Calcium Pyrophosphate
Calcium
Calcinosis
Articular Cartilage
Crystallization
Guinea Pigs
Salts
Sodium
phosphocitrate
Surveys and Questionnaires
In Vitro Techniques
calcium phosphate

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Inhibitors of articular calcium crystal formation. / Sallis, John D.; Cheung, Herman S.

In: Current Opinion in Rheumatology, Vol. 15, No. 3, 01.05.2003, p. 321-325.

Research output: Contribution to journalArticle

@article{80c367ef4061463f9ccd7392c3b04c6d,
title = "Inhibitors of articular calcium crystal formation",
abstract = "The coexistence of calcium phosphate and calcium pyrophosphate crystals in osteoarthritis is a well-described phenomenon. In addition to deposition in articular cartilage, the crystals induce numerous changes to biochemical parameters in the surrounding fluid. This survey discusses crystal-inhibitor interactions whereby defining the molecular structure of crystals assists in an optimal inhibitor design. Crystal growth studies in the presence and absence of a test compound can generate data on crystal face changes. Together with knowledge of the inhibitors' molecular structure, computer modeling can portray crystal-inhibitor interactions. Few inhibitors have been tested in both in vitro and in vivo phases. One exception is phosphocitrate. This compound inhibits both the development of specific calcium crystals and crystal-induced intracellular changes. Animal studies confirm a strong action on pathologic calcification. The recently described phosphocitrate in a mixed calcium and sodium salt, yet to be tested in a guinea pig osteoarthritis model, appears to be an even more powerful inhibitor.",
author = "Sallis, {John D.} and Cheung, {Herman S}",
year = "2003",
month = "5",
day = "1",
doi = "10.1097/00002281-200305000-00022",
language = "English",
volume = "15",
pages = "321--325",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Inhibitors of articular calcium crystal formation

AU - Sallis, John D.

AU - Cheung, Herman S

PY - 2003/5/1

Y1 - 2003/5/1

N2 - The coexistence of calcium phosphate and calcium pyrophosphate crystals in osteoarthritis is a well-described phenomenon. In addition to deposition in articular cartilage, the crystals induce numerous changes to biochemical parameters in the surrounding fluid. This survey discusses crystal-inhibitor interactions whereby defining the molecular structure of crystals assists in an optimal inhibitor design. Crystal growth studies in the presence and absence of a test compound can generate data on crystal face changes. Together with knowledge of the inhibitors' molecular structure, computer modeling can portray crystal-inhibitor interactions. Few inhibitors have been tested in both in vitro and in vivo phases. One exception is phosphocitrate. This compound inhibits both the development of specific calcium crystals and crystal-induced intracellular changes. Animal studies confirm a strong action on pathologic calcification. The recently described phosphocitrate in a mixed calcium and sodium salt, yet to be tested in a guinea pig osteoarthritis model, appears to be an even more powerful inhibitor.

AB - The coexistence of calcium phosphate and calcium pyrophosphate crystals in osteoarthritis is a well-described phenomenon. In addition to deposition in articular cartilage, the crystals induce numerous changes to biochemical parameters in the surrounding fluid. This survey discusses crystal-inhibitor interactions whereby defining the molecular structure of crystals assists in an optimal inhibitor design. Crystal growth studies in the presence and absence of a test compound can generate data on crystal face changes. Together with knowledge of the inhibitors' molecular structure, computer modeling can portray crystal-inhibitor interactions. Few inhibitors have been tested in both in vitro and in vivo phases. One exception is phosphocitrate. This compound inhibits both the development of specific calcium crystals and crystal-induced intracellular changes. Animal studies confirm a strong action on pathologic calcification. The recently described phosphocitrate in a mixed calcium and sodium salt, yet to be tested in a guinea pig osteoarthritis model, appears to be an even more powerful inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=0037732604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037732604&partnerID=8YFLogxK

U2 - 10.1097/00002281-200305000-00022

DO - 10.1097/00002281-200305000-00022

M3 - Article

C2 - 12707588

AN - SCOPUS:0037732604

VL - 15

SP - 321

EP - 325

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 3

ER -